Cited by

• Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.

  Lowes LE, Goodale D, Xia Y, Postenka C, Piaseczny MM, Paczkowski F, Allan AL. Lowes LE, et al. Onco_target. 2016 Nov 15;7(46):76125-76139. doi: 10.18632/onco_target.12682. Onco_target. 2016. PMID: 27764810 Free PMC article.
• Preclinical and Clinical Research Models of Prostate Cancer: A Brief Overview.

  Basak D, Gregori L, Johora F, Deb S. Basak D, et al. Life (Basel). 2022 Oct 14;12(10):1607. doi: 10.3390/life12101607. Life (Basel). 2022. PMID: 36295041 Free PMC article. Review.
• Cellular and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research.

  Saranyutanon S, Deshmukh SK, Dasgupta S, Pai S, Singh S, Singh AP. Saranyutanon S, et al. Cancers (Basel). 2020 Sep 17;12(9):2651. doi: 10.3390/cancers12092651. Cancers (Basel). 2020. PMID: 32957478 Free PMC article. Review.
• The human prostatic carcinoma cell line LNCaP and its derivatives. An overview.

  van Steenbrugge GJ, Groen M, van Dongen JW, Bolt J, van der Korput H, Trapman J, Hasenson M, Horoszewicz J. van Steenbrugge GJ, et al. Urol Res. 1989;17(2):71-7. doi: 10.1007/BF00262024. Urol Res. 1989. PMID: 2660395 Review.
• _targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

  Gleave ME, Zellweger T, Chi K, Miyake H, Kiyama S, July L, Leung S. Gleave ME, et al. Invest New Drugs. 2002 May;20(2):145-58. doi: 10.1023/a:1015694802521. Invest New Drugs. 2002. PMID: 12099575 Review.